99 related articles for article (PubMed ID: 34796474)
1. Rapid cGMP manufacturing of COVID-19 monoclonal antibody using stable CHO cell pools.
Agostinetto R; Rossi M; Dawson J; Lim A; Simoneau MH; Boucher C; Valldorf B; Ross-Gillespie A; Jardine JG; Sok D; Burton DR; Hassell T; Broly H; Palinsky W; Dupraz P; Feinberg M; Dey AK
Biotechnol Bioeng; 2022 Feb; 119(2):663-666. PubMed ID: 34796474
[TBL] [Abstract][Full Text] [Related]
2. Quality comparability assessment of a SARS-CoV-2-neutralizing antibody across transient, mini-pool-derived and single-clone CHO cells.
Xu G; Yu C; Wang W; Fu C; Liu H; Zhu Y; Li Y; Liu C; Fu Z; Wu G; Li M; Guo S; Yu X; Du J; Yang Y; Duan M; Cui Y; Feng H; Wang L
MAbs; 2022; 14(1):2005507. PubMed ID: 34923915
[TBL] [Abstract][Full Text] [Related]
3. A CHO stable pool production platform for rapid clinical development of trimeric SARS-CoV-2 spike subunit vaccine antigens.
Joubert S; Stuible M; Lord-Dufour S; Lamoureux L; Vaillancourt F; Perret S; Ouimet M; Pelletier A; Bisson L; Mahimkar R; Pham PL; L Ecuyer-Coelho H; Roy M; Voyer R; Baardsnes J; Sauvageau J; St-Michael F; Robotham A; Kelly J; Acel A; Schrag JD; El Bakkouri M; Durocher Y
Biotechnol Bioeng; 2023 Jul; 120(7):1746-1761. PubMed ID: 36987713
[TBL] [Abstract][Full Text] [Related]
4. Generation of High Expressing Chinese Hamster Ovary Cell Pools Using the Leap-In Transposon System.
Balasubramanian S; Peery RB; Minshull J; Lee M; White R; Kelly RM; Barnard GC
Biotechnol J; 2018 Oct; 13(10):e1700748. PubMed ID: 29797786
[TBL] [Abstract][Full Text] [Related]
5. Utilizing targeted integration CHO pools to potentially accelerate the GMP manufacturing of monoclonal and bispecific antibodies.
Barnard GC; Zhou M; Shen A; Yuk IH; Laird MW
Biotechnol Prog; 2024; 40(1):e3399. PubMed ID: 37874920
[TBL] [Abstract][Full Text] [Related]
6. Towards maximum acceleration of monoclonal antibody development: Leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable pool.
Schmieder V; Fieder J; Drerup R; Gutierrez EA; Guelch C; Stolzenberger J; Stumbaum M; Mueller VS; Higel F; Bergbauer M; Bornhoefft K; Wittner M; Gronemeyer P; Braig C; Huber M; Reisenauer-Schaupp A; Mueller MM; Schuette M; Puengel S; Lindner B; Schmidt M; Schulz P; Fischer S
J Biotechnol; 2022 Apr; 349():53-64. PubMed ID: 35341894
[TBL] [Abstract][Full Text] [Related]
7. Reproducibility and flexibility of monoclonal antibody production with
Swope K; Morton J; Pogue GP; Burden L; Partain N; Hume S; Shepherd J; Simpson CA; Brennan MB; Furman TC; Kingrey-Gebe S; Martinez T; McDonough J; Pauly MH; Whaley KJ; Zeitlin L; Bratcher B; Haydon H
MAbs; 2022; 14(1):2013594. PubMed ID: 35000569
[TBL] [Abstract][Full Text] [Related]
8. Bioreactor scale up and protein product quality characterization of piggyBac transposon derived CHO pools.
Rajendra Y; Balasubramanian S; Peery RB; Swartling JR; McCracken NA; Norris DL; Frye CC; Barnard GC
Biotechnol Prog; 2017 Mar; 33(2):534-540. PubMed ID: 28188692
[TBL] [Abstract][Full Text] [Related]
9. Accelerating and de-risking CMC development with transposon-derived manufacturing cell lines.
Rajendran S; Balasubramanian S; Webster L; Lee M; Vavilala D; Kulikov N; Choi J; Tang C; Hunter M; Wang R; Kaur H; Karunakaran S; Sitaraman V; Minshull J; Boldog F
Biotechnol Bioeng; 2021 Jun; 118(6):2301-2311. PubMed ID: 33704772
[TBL] [Abstract][Full Text] [Related]
10. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of piggyBac-mediated CHO pools to enable material generation to support GLP toxicology studies.
Rajendra Y; Balasubramanian S; McCracken NA; Norris DL; Lian Z; Schmitt MG; Frye CC; Barnard GC
Biotechnol Prog; 2017 Nov; 33(6):1436-1448. PubMed ID: 28547769
[TBL] [Abstract][Full Text] [Related]
12. A strategy to accelerate protein production from a pool of clones in Chinese hamster ovary cells for toxicology studies.
Hu Z; Hsu W; Pynn A; Ng D; Quicho D; Adem Y; Kwong Z; Mauger B; Joly J; Snedecor B; Laird MW; Andersen DC; Shen A
Biotechnol Prog; 2017 Nov; 33(6):1449-1455. PubMed ID: 28371489
[TBL] [Abstract][Full Text] [Related]
13. Enabling speed to clinic for monoclonal antibody programs using a pool of clones for IND-enabling toxicity studies.
Bolisetty P; Tremml G; Xu S; Khetan A
MAbs; 2020; 12(1):1763727. PubMed ID: 32449878
[TBL] [Abstract][Full Text] [Related]
14. Accelerating patient access to novel biologics using stable pool-derived product for non-clinical studies and single clone-derived product for clinical studies.
Munro TP; Le K; Le H; Zhang L; Stevens J; Soice N; Benchaar SA; Hong RW; Goudar CT
Biotechnol Prog; 2017 Nov; 33(6):1476-1482. PubMed ID: 29055113
[TBL] [Abstract][Full Text] [Related]
15. Rapid protein production using CHO stable transfection pools.
Ye J; Alvin K; Latif H; Hsu A; Parikh V; Whitmer T; Tellers M; de la Cruz Edmonds MC; Ly J; Salmon P; Markusen JF
Biotechnol Prog; 2010; 26(5):1431-7. PubMed ID: 20564356
[TBL] [Abstract][Full Text] [Related]
16. Leveraging a CHO cell line toolkit to accelerate biotherapeutics into the clinic.
Wright C; Alves C; Kshirsagar R; Pieracci J; Estes S
Biotechnol Prog; 2017 Nov; 33(6):1468-1475. PubMed ID: 28842948
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes.
Fu D; Zhang G; Wang Y; Zhang Z; Hu H; Shen S; Wu J; Li B; Li X; Fang Y; Liu J; Wang Q; Zhou Y; Wang W; Li Y; Lu Z; Wang X; Nie C; Tian Y; Chen D; Wang Y; Zhou X; Wang Q; Yu F; Zhang C; Deng C; Zhou L; Guan G; Shao N; Lou Z; Deng F; Zhang H; Chen X; Wang M; Liu L; Rao Z; Guo Y
PLoS Biol; 2021 May; 19(5):e3001209. PubMed ID: 33961621
[TBL] [Abstract][Full Text] [Related]
18. Recombinant CHO Cell Pool Generation Using piggyBac Transposon System.
Balasubramanian S
Methods Mol Biol; 2018; 1850():69-78. PubMed ID: 30242681
[TBL] [Abstract][Full Text] [Related]
19. Generation of stable Chinese hamster ovary pools yielding antibody titers of up to 7.6 g/L using the piggyBac transposon system.
Rajendra Y; Peery RB; Barnard GC
Biotechnol Prog; 2016 Sep; 32(5):1301-1307. PubMed ID: 27254818
[TBL] [Abstract][Full Text] [Related]
20. Attenuated glutamine synthetase as a selection marker in CHO cells to efficiently isolate highly productive stable cells for the production of antibodies and other biologics.
Lin PC; Chan KF; Kiess IA; Tan J; Shahreel W; Wong SY; Song Z
MAbs; 2019 Jul; 11(5):965-976. PubMed ID: 31043114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
